| Drug Name | Pathway ID | Pathway name | P-value | No. of gene members | UniProt AC | Gene name | Detail of Coexpression | |
|---|
| Gilteritinib | hsa00030 | Pentose phosphate pathway | 3.06E-04 | 3 | P60891, P51854, P37837 | PRPS1, TKTL1, TALDO1 | More | | | Gilteritinib | hsa00120 | Primary bile acid biosynthesis | 3.72E-02 | 2 | P22680, P22307 | CYP7A1, SCP2 | More | | | Gilteritinib | hsa00280 | Valine, leucine and isoleucine degradation | 3.41E-03 | 4 | P55809, Q9HCC0, Q02252, P11310 | OXCT1, MCCC2, ALDH6A1, ACADM | More | | | Gilteritinib | hsa00500 | Starch and sucrose metabolism | 1.47E-02 | 3 | O43451, P46976, P06737 | MGAM, GYG1, PYGL | More | | | Gilteritinib | hsa00600 | Sphingolipid metabolism | 4.23E-03 | 3 | Q9BX95, Q8TCT0, P15289 | SGPP1, CERK, ARSA | More | | | Gilteritinib | hsa00630 | Glyoxylate and dicarboxylate metabolism | 1.58E-06 | 4 | P40925, P40926, P05166, P15104 | MDH1, MDH2, PCCB, GLUL | More | | | Gilteritinib | hsa00670 | One carbon pool by folate | 1.33E-02 | 2 | P04818, Q99707 | TYMS, MTR | More | | | Gilteritinib | hsa00730 | Thiamine metabolism | 4.07E-02 | 2 | P05186, P24666 | ALPL, ACP1 | More | | | Gilteritinib | hsa00770 | Pantothenate and CoA biosynthesis | 1.15E-02 | 2 | O95498, Q9NRN7 | VNN2, AASDHPPT | More | | | Gilteritinib | hsa00900 | Terpenoid backbone biosynthesis | 4.22E-02 | 2 | P49354, Q9UHG3 | FNTA, PCYOX1 | More | | | Gilteritinib | hsa00983 | Drug metabolism - other enzymes | 1.64E-02 | 3 | P04183, P32320, P05164 | TK1, CDA, MPO | More | | | Gilteritinib | hsa01040 | Biosynthesis of unsaturated fatty acids | 2.92E-02 | 2 | P22307, Q9H5J4 | SCP2, ELOVL6 | More | | | Gilteritinib | hsa01100 | Metabolic pathways | 4.43E-02 | 23 | Q9NR34, P05089, P32320, P22748, P55809, P06280, Q16875, O43286, O43451, P05186, P24666, Q9HCC0, P33121, P57054, Q9UNP4, Q9BX95, P32321, Q9BPW9, O75911, Q9UHY7, P43490, P46976, P06737 | MAN1C1, ARG1, CDA, CA4, OXCT1, GLA, PFKFB3, B4GALT5, MGAM, ALPL, ACP1, MCCC2, ACSL1, PIGP, ST3GAL5, SGPP1, DCTD, DHRS9, DHRS3, ENOPH1, PBEF1, GYG1, PYGL | More | | | Gilteritinib | hsa01200 | Carbon metabolism | 4.32E-02 | 3 | P51854, P37837, P60891 | TKTL1, TALDO1, PRPS1 | More | | | Gilteritinib | hsa01230 | Biosynthesis of amino acids | 2.60E-02 | 3 | P51854, P60891, P37837 | TKTL1, PRPS1, TALDO1 | More | | | Gilteritinib | hsa01521 | EGFR tyrosine kinase inhibitor resistance | 1.82E-02 | 1 | P08069 | IGF1R | More | | | Gilteritinib | hsa01522 | Endocrine resistance | 1.49E-02 | 5 | P22694, Q02750, Q9UM47, P46527, P08069 | PRKACB, MAP2K1, NOTCH3, CDKN1B, IGF1R | More | | | Gilteritinib | hsa01524 | Platinum drug resistance | 4.67E-02 | 4 | Q13489, P98170, P78417, P43246 | BIRC3, BIRC4, GSTO1, MSH2 | More | | | Gilteritinib | hsa03013 | RNA transport | 7.99E-04 | 13 | P62826, Q09161, Q15287, Q9UBU9, P35658, P63279, P68104, P47813, Q14152, P55884, O75822, Q9H777, P51114 | RAN, NCBP1, RNPS1, NXF1, NUP214, UBE2I, EEF1A1, EIF1AX, EIF3A, EIF3B, EIF3J, ELAC1, FXR1 | More | | | Gilteritinib | hsa03020 | RNA polymerase | 3.00E-02 | 3 | P30876, P24928, P62487 | POLR2B, POLR2A, POLR2G | More | | | Gilteritinib | hsa03040 | Spliceosome | 6.61E-04 | 11 | Q14562, O43143, O60508, P08579, P26368, Q13595, Q07955, Q01130, P84103, Q13243, O43447 | DHX8, DHX15, CDC40, SNRPB2, U2AF2, TRA2A, SFRS1, SFRS2, SFRS3, SFRS5, PPIH | More | | | Gilteritinib | hsa03060 | Protein export | 4.42E-02 | 2 | P37108, Q15005 | SRP14, SPCS2 | More | | | Gilteritinib | hsa03430 | Mismatch repair | 4.38E-02 | 1 | P20585 | MSH3 | More | | | Gilteritinib | hsa04010 | MAPK signaling pathway | 4.15E-02 | 1 | P08069 | IGF1R | More | | | Gilteritinib | hsa04012 | ErbB signaling pathway | 1.91E-02 | 3 | P16333, P19174, P01106 | NCK1, PLCG1, MYC | More | | | Gilteritinib | hsa04014 | Ras signaling pathway | 1.64E-02 | 7 | Q02750, Q15389, P08069, P17252, P21359, P62879, P22694 | MAP2K1, ANGPT1, IGF1R, PRKCA, NF1, GNB2, PRKACB | More | | | Gilteritinib | hsa04015 | Rap1 signaling pathway | 5.18E-04 | 3 | P08069, P06213, O00522 | IGF1R, INSR, KRIT1 | More | | | Gilteritinib | hsa04020 | Calcium signaling pathway | 1.24E-02 | 6 | Q96DU7, Q08828, Q13557, P21860, P0DP24, P05141 | ITPKC, ADCY1, CAMK2D, ERBB3, CALM2, SLC25A5 | More | | | Gilteritinib | hsa04022 | cGMP-PKG signaling pathway | 2.84E-02 | 6 | Q02153, Q99941, P18848, Q08828, P05141, P0DP24 | GUCY1B3, CREBL1, ATF4, ADCY1, SLC25A5, CALM2 | More | | | Gilteritinib | hsa04062 | Chemokine signaling pathway | 3.81E-02 | 6 | P07948, P62873, P63218, P50151, P43250, Q13009 | LYN, GNB1, GNG5, GNG10, GRK6, TIAM1 | More | | | Gilteritinib | hsa04064 | NF-kappa B signaling pathway | 2.28E-03 | 11 | O00463, P14778, P01584, Q13077, Q16548, Q8WV28, P63279, P24522, Q8NHW4, P09341, Q9NQC7 | TRAF5, IL1R1, IL1B, TRAF1, BCL2A1, BLNK, UBE2I, GADD45A, CCL4L2, CXCL1, CYLD | More | | | Gilteritinib | hsa04066 | HIF-1 signaling pathway | 1.49E-02 | 5 | P08069, P17252, Q15389, Q02750, P46527 | IGF1R, PRKCA, ANGPT1, MAP2K1, CDKN1B | More | | | Gilteritinib | hsa04068 | FoxO signaling pathway | 1.99E-02 | 1 | P08069 | IGF1R | More | | | Gilteritinib | hsa04071 | Sphingolipid signaling pathway | 1.19E-02 | 4 | P21453, Q9H228, P01375, Q13362 | S1PR1, EDG8, TNF, PPP2R5C | More | | | Gilteritinib | hsa04080 | Neuroactive ligand-receptor interaction | 1.97E-02 | 5 | P28472, P21453, Q9H228, P21730, P07550 | GABRB3, S1PR1, EDG8, C5AR1, ADRB2 | More | | | Gilteritinib | hsa04110 | Cell cycle | 2.06E-02 | 6 | Q9UBD5, P06493, Q14683, P30304, P33981, P01106 | ORC3, CDK1, SMC1A, CDC25A, TTK, MYC | More | | | Gilteritinib | hsa04114 | Oocyte meiosis | 2.99E-02 | 1 | P08069 | IGF1R | More | | | Gilteritinib | hsa04120 | Ubiquitin mediated proteolysis | 3.44E-02 | 4 | Q14145, Q13042, P62837, Q15751 | KEAP1, CDC16, UBE2D2, HERC1 | More | | | Gilteritinib | hsa04140 | Autophagy - animal | 2.82E-02 | 1 | P08069 | IGF1R | More | | | Gilteritinib | hsa04141 | Protein processing in endoplasmic reticulum | 3.96E-02 | 7 | P18848, Q15436, Q99941, P11142, Q9H3Z4, P07900, Q9NR31 | ATF4, SEC23A, CREBL1, HSPA8, DNAJC5, HSP90AA1, SAR1A | More | | | Gilteritinib | hsa04142 | Lysosome | 1.46E-02 | 7 | P06865, P22304, P38571, Q13510, P07602, Q9NRA2, P61916 | HEXA, IDS, LIPA, ASAH1, PSAP, SLC17A5, NPC2 | More | | | Gilteritinib | hsa04144 | Endocytosis | 1.67E-02 | 8 | P0DMV8, Q9H444, O75351, P62491, Q96B97, Q15438, Q14161, Q9UMY4 | HSPA1A, CHMP4B, VPS4B, RAB11A, SH3KBP1, PSCD1, GIT2, SNX12 | More | | | Gilteritinib | hsa04150 | mTOR signaling pathway | 2.32E-02 | 1 | P08069 | IGF1R | More | | | Gilteritinib | hsa04151 | PI3K-Akt signaling pathway | 2.21E-02 | 10 | P62753, P21860, P27348, P07900, P62873, P61952, Q16363, P22105, Q99941, P18848 | RPS6, ERBB3, YWHAQ, HSP90AA1, GNB1, GNG11, LAMA4, TNXB, CREBL1, ATF4 | More | | | Gilteritinib | hsa04152 | AMPK signaling pathway | 1.99E-02 | 1 | P08069 | IGF1R | More | | | Gilteritinib | hsa04211 | Longevity regulating pathway | 2.16E-02 | 1 | P08069 | IGF1R | More | | | Gilteritinib | hsa04213 | Longevity regulating pathway - multiple species | 8.54E-03 | 4 | P08069, Q08828, P51828, P0DMV8 | IGF1R, ADCY1, ADCY7, HSPA1A | More | | | Gilteritinib | hsa04217 | Necroptosis | 1.32E-04 | 15 | P01375, P01568, P48023, Q13489, P98170, Q14765, P07900, P08238, P15104, P05141, P01584, P0C0S5, Q99878, Q13557, P21796 | TNF, IFNA21, FASLG, BIRC3, BIRC4, STAT4, HSP90AA1, HSP90AB1, GLUL, SLC25A5, IL1B, H2AFZ, H2AC14, CAMK2D, VDAC1 | More | | | Gilteritinib | hsa04261 | Adrenergic signaling in cardiomyocytes | 2.95E-02 | 4 | P07550, P22694, P18848, Q13362 | ADRB2, PRKACB, ATF4, PPP2R5C | More | | | Gilteritinib | hsa04270 | Vascular smooth muscle contraction | 6.96E-03 | 6 | P0DP23, Q08828, P51828, P35579, P35749, P35318 | CALM1, ADCY1, ADCY7, MYH9, MYH11, ADM | More | | | Gilteritinib | hsa04371 | Apelin signaling pathway | 6.39E-05 | 11 | P62873, P63218, P50151, P61952, Q08828, Q13485, P84022, P62753, Q16566, P0DP23, P0DP24 | GNB1, GNG5, GNG10, GNG11, ADCY1, SMAD4, SMAD3, RPS6, CAMK4, CALM1, CALM2 | More | | | Gilteritinib | hsa04392 | Hippo signaling pathway - multiple species | 3.01E-02 | 1 | Q6V0I7 | FAT4 | More | | | Gilteritinib | hsa04510 | Focal adhesion | 3.48E-02 | 1 | P08069 | IGF1R | More | | | Gilteritinib | hsa04520 | Adherens junction | 8.29E-03 | 1 | P08069 | IGF1R | More | | | Gilteritinib | hsa04540 | Gap junction | 2.03E-02 | 4 | P17252, P22694, P68371, Q02750 | PRKCA, PRKACB, TUBB2C, MAP2K1 | More | | | Gilteritinib | hsa04550 | Signaling pathways regulating pluripotency of stem cells | 1.99E-02 | 1 | P08069 | IGF1R | More | | | Gilteritinib | hsa04612 | Antigen processing and presentation | 1.07E-03 | 6 | Q14953, P26715, P26717, Q13241, P01732, P01375 | KIR2DS5, KLRC1, KLRC2, KLRD1, CD8A, TNF | More | | | Gilteritinib | hsa04623 | Cytosolic DNA-sensing pathway | 1.65E-02 | 2 | P01584, Q8NHW4 | IL1B, CCL4L2 | More | | | Gilteritinib | hsa04650 | Natural killer cell mediated cytotoxicity | 5.05E-04 | 7 | P01375, P20963, Q13241, P26718, P26717, Q14953, P26715 | TNF, CD247, KLRD1, KLRK1, KLRC2, KIR2DS5, KLRC1 | More | | | Gilteritinib | hsa04657 | IL-17 signaling pathway | 3.33E-03 | 8 | O00463, Q16539, P49841, P09341, P19875, P14780, P80188, P01375 | TRAF5, MAPK14, GSK3B, CXCL1, CXCL2, MMP9, LCN2, TNF | More | | | Gilteritinib | hsa04662 | B cell receptor signaling pathway | 1.49E-03 | 5 | P42338, P60033, P07948, P21854, Q8N149 | PIK3CB, CD81, LYN, CD72, LILRA2 | More | | | Gilteritinib | hsa04664 | Fc epsilon RI signaling pathway | 2.32E-02 | 3 | P42338, P07948, P09917 | PIK3CB, LYN, ALOX5 | More | | | Gilteritinib | hsa04668 | TNF signaling pathway | 1.48E-03 | 8 | P01375, Q99941, P18848, P19875, P01584, P14780, P20333, O95429 | TNF, CREBL1, ATF4, CXCL2, IL1B, MMP9, TNFRSF1B, BAG4 | More | | | Gilteritinib | hsa04713 | Circadian entrainment | 2.36E-06 | 10 | O15399, P0DP23, P0DP24, Q13557, Q02153, P62873, P63218, P50151, P61952, Q08828 | GRIN2D, CALM1, CALM2, CAMK2D, GUCY1B3, GNB1, GNG5, GNG10, GNG11, ADCY1 | More | | | Gilteritinib | hsa04720 | Long-term potentiation | 4.01E-05 | 11 | P17252, Q16566, Q13557, P0DP23, P0DP24, P51812, P18848, O15399, P22694, Q08828, Q02750 | PRKCA, CAMK4, CAMK2D, CALM1, CALM2, RPS6KA3, ATF4, GRIN2D, PRKACB, ADCY1, MAP2K1 | More | | | Gilteritinib | hsa04722 | Neurotrophin signaling pathway | 3.27E-02 | 3 | P49841, O43524, P48023 | GSK3B, FOXO3, FASLG | More | | | Gilteritinib | hsa04723 | Retrograde endocannabinoid signaling | 3.71E-02 | 4 | P62873, P61952, Q08828, O15239 | GNB1, GNG11, ADCY1, NDUFA1 | More | | | Gilteritinib | hsa04724 | Glutamatergic synapse | 1.73E-06 | 7 | O15399, Q08828, P62873, P63218, P50151, P61952, P15104 | GRIN2D, ADCY1, GNB1, GNG5, GNG10, GNG11, GLUL | More | | | Gilteritinib | hsa04725 | Cholinergic synapse | 2.09E-06 | 13 | Q08828, P22694, P17252, P62873, P62879, P63218, P50151, P61952, P18848, Q16566, Q13557, P42338, Q02750 | ADCY1, PRKACB, PRKCA, GNB1, GNB2, GNG5, GNG10, GNG11, ATF4, CAMK4, CAMK2D, PIK3CB, MAP2K1 | More | | | Gilteritinib | hsa04726 | Serotonergic synapse | 1.39E-03 | 8 | P22694, P17252, P62873, P62879, P63218, P50151, P09917, Q02750 | PRKACB, PRKCA, GNB1, GNB2, GNG5, GNG10, ALOX5, MAP2K1 | More | | | Gilteritinib | hsa04727 | GABAergic synapse | 3.46E-07 | 11 | Q08828, P62873, P62879, P63218, P50151, P61952, P15104, P22694, O60296, Q15111, P17252 | ADCY1, GNB1, GNB2, GNG5, GNG10, GNG11, GLUL, PRKACB, TRAK2, PLCL1, PRKCA | More | | | Gilteritinib | hsa04728 | Dopaminergic synapse | 1.62E-03 | 7 | P62873, P61952, Q99941, P18848, Q13557, P0DP24, O15516 | GNB1, GNG11, CREBL1, ATF4, CAMK2D, CALM2, CLOCK | More | | | Gilteritinib | hsa04730 | Long-term depression | 1.16E-02 | 1 | P08069 | IGF1R | More | | | Gilteritinib | hsa04740 | Olfactory transduction | 1.17E-03 | 4 | P62873, Q9H255, Q13557, P0DP24 | GNB1, OR51E2, CAMK2D, CALM2 | More | | | Gilteritinib | hsa04742 | Taste transduction | 1.01E-02 | 1 | P30939 | HTR1F | More | | | Gilteritinib | hsa04744 | Phototransduction | 4.87E-04 | 3 | P62873, P0DP23, P0DP24 | GNB1, CALM1, CALM2 | More | | | Gilteritinib | hsa04750 | Inflammatory mediator regulation of TRP channels | 3.60E-03 | 6 | P01584, Q08828, P51828, Q13557, P0DP23, P0DP24 | IL1B, ADCY1, ADCY7, CAMK2D, CALM1, CALM2 | More | | | Gilteritinib | hsa04911 | Insulin secretion | 1.06E-02 | 4 | Q08828, Q99941, P18848, Q13557 | ADCY1, CREBL1, ATF4, CAMK2D | More | | | Gilteritinib | hsa04913 | Ovarian steroidogenesis | 5.67E-04 | 4 | P42330, P22694, P06213, P08069 | AKR1C3, PRKACB, INSR, IGF1R | More | | | Gilteritinib | hsa04914 | Progesterone-mediated oocyte maturation | 2.16E-02 | 1 | P08069 | IGF1R | More | | | Gilteritinib | hsa04915 | Estrogen signaling pathway | 2.49E-03 | 10 | Q99941, P18848, Q08828, P51828, P07900, P0DMV8, P11142, P0DP23, P0DP24, Q15788 | CREBL1, ATF4, ADCY1, ADCY7, HSP90AA1, HSPA1A, HSPA8, CALM1, CALM2, NCOA1 | More | | | Gilteritinib | hsa04918 | Thyroid hormone synthesis | 3.71E-02 | 4 | Q08828, Q99941, P18848, P02768 | ADCY1, CREBL1, ATF4, ALB | More | | | Gilteritinib | hsa04919 | Thyroid hormone signaling pathway | 2.22E-02 | 5 | P17252, Q02750, P22694, Q12778, Q9UM47 | PRKCA, MAP2K1, PRKACB, FOXO1, NOTCH3 | More | | | Gilteritinib | hsa04923 | Regulation of lipolysis in adipocytes | 3.76E-02 | 1 | P06213 | INSR | More | | | Gilteritinib | hsa04924 | Renin secretion | 4.04E-02 | 2 | P22694, P07550 | PRKACB, ADRB2 | More | | | Gilteritinib | hsa04925 | Aldosterone synthesis and secretion | 6.67E-03 | 5 | Q99941, P18848, Q08828, P0DP24, Q13557 | CREBL1, ATF4, ADCY1, CALM2, CAMK2D | More | | | Gilteritinib | hsa04926 | Relaxin signaling pathway | 2.98E-05 | 13 | P42338, P62873, P63218, P50151, P61952, Q99941, P18848, P22694, P49767, P14780, Q08828, P30679, P49407 | PIK3CB, GNB1, GNG5, GNG10, GNG11, CREBL1, ATF4, PRKACB, VEGFC, MMP9, ADCY1, GNA15, ARRB1 | More | | | Gilteritinib | hsa04927 | Cortisol synthesis and secretion | 1.99E-03 | 4 | Q99941, P18848, Q08828, P22694 | CREBL1, ATF4, ADCY1, PRKACB | More | | | Gilteritinib | hsa04928 | Parathyroid hormone synthesis, secretion and action | 4.48E-02 | 4 | P22694, Q02750, P17252, Q9Y5Q3 | PRKACB, MAP2K1, PRKCA, MAFB | More | | | Gilteritinib | hsa04929 | GnRH secretion | 4.62E-02 | 2 | P42338, P49407 | PIK3CB, ARRB1 | More | | | Gilteritinib | hsa04930 | Type II diabetes mellitus | 3.14E-02 | 1 | P06213 | INSR | More | | | Gilteritinib | hsa04932 | Non-alcoholic fatty liver disease | 1.16E-04 | 11 | P01375, P49841, O43521, P18848, P48023, O75460, P01584, P13073, P12074, O15239, O95298 | TNF, GSK3B, BCL2L11, ATF4, FASLG, ERN1, IL1B, COX4I1, COX6A1, NDUFA1, NDUFC2 | More | | | Gilteritinib | hsa04934 | Cushing syndrome | 2.60E-02 | 4 | Q99941, P18848, Q08828, Q13557 | CREBL1, ATF4, ADCY1, CAMK2D | More | | | Gilteritinib | hsa04940 | Type I diabetes mellitus | 1.87E-02 | 2 | P48023, P01375 | FASLG, TNF | More | | | Gilteritinib | hsa04960 | Aldosterone-regulated sodium reabsorption | 3.14E-02 | 1 | P06213 | INSR | More | | | Gilteritinib | hsa04970 | Salivary secretion | 3.45E-05 | 9 | P07550, Q08828, P51828, P22694, P17252, P0DP23, P0DP24, Q02153, P49913 | ADRB2, ADCY1, ADCY7, PRKACB, PRKCA, CALM1, CALM2, GUCY1B3, CAMP | More | | | Gilteritinib | hsa04976 | Bile secretion | 4.78E-02 | 3 | Q08828, P51828, Q14032 | ADCY1, ADCY7, BAAT | More | | | Gilteritinib | hsa05012 | Parkinson disease | 4.13E-02 | 8 | O15239, P13073, P12074, P05496, P05141, P18848, P0DP24, Q13557 | NDUFA1, COX4I1, COX6A1, ATP5G1, SLC25A5, ATF4, CALM2, CAMK2D | More | | | Gilteritinib | hsa05016 | Huntington disease | 2.46E-02 | 9 | O95298, P13073, P12074, P24928, P30876, P62487, O75460, P28070, O00232 | NDUFC2, COX4I1, COX6A1, POLR2A, POLR2B, POLR2G, ERN1, PSMB4, PSMD12 | More | | | Gilteritinib | hsa05020 | Prion disease | 1.86E-02 | 10 | P01584, P46531, P11142, O15239, P05496, P13073, P12074, P18848, P05141, Q99941 | IL1B, NOTCH1, HSPA8, NDUFA1, ATP5G1, COX4I1, COX6A1, ATF4, SLC25A5, CREBL1 | More | | | Gilteritinib | hsa05022 | Pathways of neurodegeneration - multiple diseases | 2.95E-02 | 2 | Q06055, O15020 | ATP5G2, SPTBN2 | More | | | Gilteritinib | hsa05031 | Amphetamine addiction | 1.52E-03 | 6 | P0DP24, Q13557, P22694, Q99941, P18848, Q13547 | CALM2, CAMK2D, PRKACB, CREBL1, ATF4, HDAC1 | More | | | Gilteritinib | hsa05032 | Morphine addiction | 1.34E-02 | 4 | P62873, P63218, P50151, P43250 | GNB1, GNG5, GNG10, GRK6 | More | | | Gilteritinib | hsa05034 | Alcoholism | 1.12E-04 | 12 | O15399, Q99941, P18848, Q16566, P0DP23, P0DP24, P62873, P63218, P50151, P61952, P0C0S5, Q93079 | GRIN2D, CREBL1, ATF4, CAMK4, CALM1, CALM2, GNB1, GNG5, GNG10, GNG11, H2AFZ, H2BC9 | More | | | Gilteritinib | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 2.45E-02 | 4 | Q16539, P09341, P25024, P25025 | MAPK14, CXCL1, CXCR1, CXCR2 | More | | | Gilteritinib | hsa05134 | Legionellosis | 1.77E-03 | 5 | P01584, Q9NR31, P68104, P0DMV8, P11142 | IL1B, SAR1A, EEF1A1, HSPA1A, HSPA8 | More | | | Gilteritinib | hsa05140 | Leishmaniasis | 2.69E-02 | 5 | O75015, P13765, O60603, P49006, Q16539 | FCGR3B, HLA-DOB, TLR2, MARCKSL1, MAPK14 | More | | | Gilteritinib | hsa05143 | African trypanosomiasis | 2.72E-02 | 2 | P01375, P48023 | TNF, FASLG | More | | | Gilteritinib | hsa05144 | Malaria | 1.91E-02 | 3 | P01375, P35443, P26718 | TNF, THBS4, KLRK1 | More | | | Gilteritinib | hsa05146 | Amoebiasis | 3.33E-03 | 9 | P09341, P19875, P14778, P27930, P01375, O60603, P05089, P30679, P22694 | CXCL1, CXCL2, IL1R1, IL1R2, TNF, TLR2, ARG1, GNA15, PRKACB | More | | | Gilteritinib | hsa05150 | Staphylococcus aureus infection | 2.44E-02 | 4 | P21462, Q14532, P59665, P59666 | FPR1, KRT32, DEFA1; DEFA1B, DEFA3 | More | | | Gilteritinib | hsa05160 | Hepatitis C | 1.27E-02 | 4 | P60033, P49841, P01375, P48023 | CD81, GSK3B, TNF, FASLG | More | | | Gilteritinib | hsa05162 | Measles | 3.18E-02 | 4 | P23458, P0DMV8, P01584, Q9NP90 | JAK1, HSPA1A, IL1B, RAB9B | More | | | Gilteritinib | hsa05163 | Human cytomegalovirus infection | 1.99E-05 | 24 | P62873, P63218, P50151, P61952, Q14643, P0DP23, P0DP24, Q8NHW4, Q08828, P51828, P23458, P49841, P14778, P01584, Q13651, P25025, Q16539, Q99941, P18848, P04637, O00463, P30101, P61769, P01568 | GNB1, GNG5, GNG10, GNG11, ITPR1, CALM1, CALM2, CCL4L2, ADCY1, ADCY7, JAK1, GSK3B, IL1R1, IL1B, IL10RA, CXCR2, MAPK14, CREBL1, ATF4, TP53, TRAF5, PDIA3, B2M, IFNA21 | More | | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
|---|
| Q96KQ7 | EHMT2 | Histone-lysine N-methyltransferase EHMT2 | P62873 | GNB1 | Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1 | -0.709 | | Q13557 | CAMK2D | Calcium/calmodulin-dependent protein kinase type II subunit delta | P62873 | GNB1 | Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1 | 0.789 | | Q96KQ7 | EHMT2 | Histone-lysine N-methyltransferase EHMT2 | P63218 | GNG5 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-5 | 0.759 | | Q96KQ7 | EHMT2 | Histone-lysine N-methyltransferase EHMT2 | P50151 | GNG10 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-10 | 0.744 | | Q13557 | CAMK2D | Calcium/calmodulin-dependent protein kinase type II subunit delta | P61952 | GNG11 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-11 | -0.756 | | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | Q14643 | ITPR1 | Inositol 1,4,5-trisphosphate receptor type 1 | -0.728 | | P23458 | JAK1 | Tyrosine-protein kinase JAK1 | P0DP23 | CALM1 | Calmodulin-1 | 0.822 | | Q96KQ7 | EHMT2 | Histone-lysine N-methyltransferase EHMT2 | P0DP23 | CALM1 | Calmodulin-1 | -0.724 | | Q13557 | CAMK2D | Calcium/calmodulin-dependent protein kinase type II subunit delta | P0DP24 | CALM2 | Calmodulin-2 | 0.786 | | P23458 | JAK1 | Tyrosine-protein kinase JAK1 | Q8NHW4 | CCL4L2 | C-C motif chemokine 4-like | 0.802 | | P23458 | JAK1 | Tyrosine-protein kinase JAK1 | Q8NHW4 | CCL4L2 | C-C motif chemokine 4-like | 0.802 | | P23458 | JAK1 | Tyrosine-protein kinase JAK1 | Q08828 | ADCY1 | Adenylate cyclase type 1 | 0.84 | | Q13557 | CAMK2D | Calcium/calmodulin-dependent protein kinase type II subunit delta | Q08828 | ADCY1 | Adenylate cyclase type 1 | 0.75 | | P23458 | JAK1 | Tyrosine-protein kinase JAK1 | P51828 | ADCY7 | Adenylate cyclase type 7 | 0.834 | | P23458 | JAK1 | Tyrosine-protein kinase JAK1 | P23458 | JAK1 | Tyrosine-protein kinase JAK1 | 1 | | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P49841 | GSK3B | Glycogen synthase kinase-3 beta | 0.78 | | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P14778 | IL1R1 | Interleukin-1 receptor type 1 | 0.76 | | P23458 | JAK1 | Tyrosine-protein kinase JAK1 | P01584 | IL1B | Interleukin-1 beta | 0.799 | | Q13557 | CAMK2D | Calcium/calmodulin-dependent protein kinase type II subunit delta | P01584 | IL1B | Interleukin-1 beta | 0.725 | | P23458 | JAK1 | Tyrosine-protein kinase JAK1 | Q13651 | IL10RA | Interleukin-10 receptor subunit alpha | 0.799 | | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | 0.889 | | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 1 | | Q13557 | CAMK2D | Calcium/calmodulin-dependent protein kinase type II subunit delta | Q99941 | CREBL1 | Cyclic AMP-dependent transcription factor ATF-6 beta | 0.801 | | Q13557 | CAMK2D | Calcium/calmodulin-dependent protein kinase type II subunit delta | P18848 | ATF4 | Cyclic AMP-dependent transcription factor ATF-4 | 0.844 | | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P04637 | TP53 | Cellular tumor antigen p53 | -0.823 | | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | O00463 | TRAF5 | TNF receptor-associated factor 5 | -0.837 | | Q96KQ7 | EHMT2 | Histone-lysine N-methyltransferase EHMT2 | P30101 | PDIA3 | Protein disulfide-isomerase A3 | -0.825 | | Q13557 | CAMK2D | Calcium/calmodulin-dependent protein kinase type II subunit delta | P61769 | B2M | Beta-2-microglobulin | 0.753 | | Q96KQ7 | EHMT2 | Histone-lysine N-methyltransferase EHMT2 | P01568 | IFNA21 | Interferon alpha-21 | 0.703 |
| | Gilteritinib | hsa05165 | Human papillomavirus infection | 4.71E-03 | 10 | P46527, Q02750, P35443, Q92796, Q05086, Q9UM47, P22694, Q13362, Q12778, Q13315 | CDKN1B, MAP2K1, THBS4, DLG3, UBE3A, NOTCH3, PRKACB, PPP2R5C, FOXO1, ATM | More | | | Gilteritinib | hsa05167 | Kaposi sarcoma-associated herpesvirus infection | 2.00E-02 | 6 | P01568, P62873, P63218, P50151, P07948, P0DP23 | IFNA21, GNB1, GNG5, GNG10, LYN, CALM1 | More | | | Gilteritinib | hsa05168 | Herpes simplex virus 1 infection | 4.43E-02 | 8 | P01568, Q07955, P84103, Q13243, Q13489, P30101, Q13398, Q9NZL3 | IFNA21, SFRS1, SFRS3, SFRS5, BIRC3, PDIA3, ZNF211, ZNF224 | More | | | Gilteritinib | hsa05169 | Epstein-Barr virus infection | 3.72E-02 | 6 | Q13547, P42338, P07948, Q13761, O75293, P07766 | HDAC1, PIK3CB, LYN, RUNX3, GADD45B, CD3E | More | | | Gilteritinib | hsa05170 | Human immunodeficiency virus 1 infection | 1.83E-02 | 7 | P62873, P63218, P50151, P0DP23, P30101, P01568, P23528 | GNB1, GNG5, GNG10, CALM1, PDIA3, IFNA21, CFL1 | More | | | Gilteritinib | hsa05200 | Pathways in cancer | 3.99E-04 | 15 | Q13751, P08238, P43246, P84022, Q13485, Q13489, P98170, P62873, P63218, P50151, P78417, O75293, P0DP23, P01568, P01042 | LAMB3, HSP90AB1, MSH2, SMAD3, SMAD4, BIRC3, BIRC4, GNB1, GNG5, GNG10, GSTO1, GADD45B, CALM1, IFNA21, KNG1 | More | | | Gilteritinib | hsa05202 | Transcriptional misregulation in cancer | 7.84E-03 | 8 | Q12778, Q13315, Q15744, P08069, P46527, P05164, P08246, Q9C0K0 | FOXO1, ATM, CEBPE, IGF1R, CDKN1B, MPO, ELA2, BCL11B | More | | | Gilteritinib | hsa05205 | Proteoglycans in cancer | 1.09E-02 | 6 | P14780, P01375, P08069, P23588, Q13635, P22694 | MMP9, TNF, IGF1R, EIF4B, PTCH1, PRKACB | More | | | Gilteritinib | hsa05206 | MicroRNAs in cancer | 3.66E-02 | 6 | P46527, Q9UM47, P16070, Q13315, P17252, Q02750 | CDKN1B, NOTCH3, CD44, ATM, PRKCA, MAP2K1 | More | | | Gilteritinib | hsa05210 | Colorectal cancer | 4.67E-02 | 4 | P84022, Q13485, P43246, O75293 | SMAD3, SMAD4, MSH2, GADD45B | More | | | Gilteritinib | hsa05212 | Pancreatic cancer | 3.28E-02 | 3 | P84022, Q13485, O75293 | SMAD3, SMAD4, GADD45B | More | | | Gilteritinib | hsa05214 | Glioma | 4.50E-03 | 4 | P08069, P0DP23, Q16566, O75293 | IGF1R, CALM1, CAMK4, GADD45B | More | | | Gilteritinib | hsa05215 | Prostate cancer | 1.33E-02 | 1 | P08069 | IGF1R | More | | | Gilteritinib | hsa05218 | Melanoma | 6.63E-03 | 1 | P08069 | IGF1R | More | | | Gilteritinib | hsa05219 | Bladder cancer | 4.07E-02 | 2 | P14780, P04637 | MMP9, TP53 | More | | | Gilteritinib | hsa05222 | Small cell lung cancer | 3.80E-02 | 4 | Q13751, Q13489, P98170, O75293 | LAMB3, BIRC3, BIRC4, GADD45B | More | | | Gilteritinib | hsa05224 | Breast cancer | 1.24E-02 | 5 | P08069, P49841, Q92837, P04637, P24522 | IGF1R, GSK3B, FRAT1, TP53, GADD45A | More | | | Gilteritinib | hsa05225 | Hepatocellular carcinoma | 1.33E-02 | 1 | P08069 | IGF1R | More | | | Gilteritinib | hsa05231 | Choline metabolism in cancer | 2.60E-02 | 3 | Q9Y259, P19174, P49619 | CHKB, PLCG1, DGKG | More | | | Gilteritinib | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 4.55E-02 | 5 | O95267, P09693, O60603, Q16539, P01730 | RASGRP1, CD3G, TLR2, MAPK14, CD4 | More | | | Gilteritinib | hsa05321 | Inflammatory bowel disease | 1.91E-02 | 3 | P01375, Q14765, Q9UL17 | TNF, STAT4, TBX21 | More | | | Gilteritinib | hsa05330 | Allograft rejection | 2.72E-02 | 2 | P48023, P01375 | FASLG, TNF | More | | | Gilteritinib | hsa05332 | Graft-versus-host disease | 7.27E-04 | 4 | P48023, P01375, P26715, Q13241 | FASLG, TNF, KLRC1, KLRD1 | More | | | Gilteritinib | hsa05418 | Fluid shear stress and atherosclerosis | 2.62E-02 | 6 | Q16539, P10599, P14780, P04637, P14778, P27930 | MAPK14, TXN, MMP9, TP53, IL1R1, IL1R2 | More | |
|
